振东制药涨2.09%，成交额1.67亿元，主力资金净流入36.88万元

Core Viewpoint - Zhendong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 58.56%, but recent declines in the short term indicate potential challenges ahead [1][2]. Financial Performance - For the period from January to September 2025, Zhendong Pharmaceutical reported a revenue of 2.215 billion yuan, reflecting a year-on-year decrease of 2.42%. The net profit attributable to shareholders was 20.3641 million yuan, down 49.25% year-on-year [2]. - The company has not distributed any dividends in the past three years, with a total payout of 3.372 billion yuan since its A-share listing [3]. Stock Market Activity - As of October 29, Zhendong Pharmaceutical's stock price was 6.85 yuan per share, with a market capitalization of 6.886 billion yuan. The stock experienced a trading volume of 1.67 billion yuan and a turnover rate of 2.46% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent instance on August 11, where it recorded a net purchase of 866.539 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 48,400, with an average of 20,762 circulating shares per person, a decrease of 4.66% from the previous period [2]. - Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 37.46 million shares, an increase of 29.4896 million shares from the previous period [3]. Business Overview - Zhendong Pharmaceutical, established on November 15, 1995, and listed on January 7, 2011, operates in the pharmaceutical sector, focusing on the research, production, and sales of generic and innovative drugs across various therapeutic areas [2]. - The company's revenue composition includes 54.82% from traditional Chinese medicine, 43.10% from chemical drugs, and 1.98% from other sources [2].